Focus Partners Advisor Solutions LLC Purchases 20,225 Shares of Pfizer Inc. $PFE

Focus Partners Advisor Solutions LLC boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 16.3% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 144,571 shares of the biopharmaceutical company's stock after purchasing an additional 20,225 shares during the period. Focus Partners Advisor Solutions LLC's holdings in Pfizer were worth $3,663,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. First Financial Bankshares Inc grew its position in Pfizer by 4.7% in the 1st quarter. First Financial Bankshares Inc now owns 416,170 shares of the biopharmaceutical company's stock worth $10,546,000 after purchasing an additional 18,696 shares in the last quarter. Beck Mack & Oliver LLC grew its position in Pfizer by 1.7% in the 1st quarter. Beck Mack & Oliver LLC now owns 87,506 shares of the biopharmaceutical company's stock worth $2,217,000 after purchasing an additional 1,500 shares in the last quarter. Graham Capital Management L.P. bought a new stake in Pfizer in the 1st quarter worth about $2,086,000. Armistice Capital LLC bought a new stake in Pfizer in the 1st quarter worth about $5,365,000. Finally, Retirement Planning Co of New England Inc. grew its position in Pfizer by 3.8% in the 1st quarter. Retirement Planning Co of New England Inc. now owns 25,630 shares of the biopharmaceutical company's stock worth $649,000 after purchasing an additional 935 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $24.74 on Tuesday. The stock has a market capitalization of $140.65 billion, a P/E ratio of 13.16, a PEG ratio of 0.88 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm's 50 day moving average is $24.81 and its 200 day moving average is $24.36. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's dividend payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. Bank of America boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Berenberg Bank dropped their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.